These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors. Shah T; Lai WK; Mutimer D Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091 [TBL] [Abstract][Full Text] [Related]
3. Costs and consequences of cytomegalovirus disease. Schnitzler MA Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228 [TBL] [Abstract][Full Text] [Related]
4. A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation cytomegalovirus. Pescovitz MD Kidney Int; 2007 Oct; 72(8):912-3. PubMed ID: 17914417 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
6. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir. Prian GW; Koep LJ Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977 [No Abstract] [Full Text] [Related]
7. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients. Oppenheimer F; Gonzalez-Molina M; Rubio M Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Mauskopf JA; Richter A; Annemans L; Maclaine G Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391 [TBL] [Abstract][Full Text] [Related]
10. Preemptive therapy for cytomegalovirus with oral ganciclovir after liver transplantation. Singh N Transplantation; 2002 Jun; 73(12):1977; author reply 1977-8. PubMed ID: 12131704 [No Abstract] [Full Text] [Related]
11. AIDS research "spin-off"--ganciclovir CMV prevention after liver transplantation. James JS AIDS Treat News; 1995 Jul; (no 227):6. PubMed ID: 11362621 [TBL] [Abstract][Full Text] [Related]
12. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344 [TBL] [Abstract][Full Text] [Related]
14. Acyclovir and ganciclovir in cytomegalovirus. Moss GB Ann Intern Med; 1994 Sep; 121(5):385. PubMed ID: 8042835 [No Abstract] [Full Text] [Related]
15. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438 [TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus prevention strategies: the case for prophylaxis. Snydman DR Am J Transplant; 2009 May; 9(5):1254. PubMed ID: 19422353 [No Abstract] [Full Text] [Related]
17. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Winston DJ; Busuttil RW Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998 [TBL] [Abstract][Full Text] [Related]
18. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790 [TBL] [Abstract][Full Text] [Related]
19. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314 [TBL] [Abstract][Full Text] [Related]